152 related articles for article (PubMed ID: 12474372)
1. [80,000 patients with arthrosis treated. Coxib gets through a practice test, too].
MMW Fortschr Med; 2002 Oct; 144(41):60. PubMed ID: 12474372
[No Abstract] [Full Text] [Related]
2. [Gastrointestinal complications caused by NSAIDs. Over 60% of arthrosis patients are endangered].
MMW Fortschr Med; 2003 Mar; 145(10):60. PubMed ID: 12688036
[No Abstract] [Full Text] [Related]
3. [Cox-2 inhibitors in the focus. Rofecoxib as effective as the "classics"].
MMW Fortschr Med; 2001 Nov; 143(46):50-1. PubMed ID: 11759601
[No Abstract] [Full Text] [Related]
4. Tailoring arthritis therapy in the wake of the NSAID crisis.
Olsen NJ
N Engl J Med; 2005 Jun; 352(25):2578-80. PubMed ID: 15972863
[No Abstract] [Full Text] [Related]
5. [Side effects cause enormous costs. Expensive arthritis therapy].
MMW Fortschr Med; 2001 Nov; 143(46):60. PubMed ID: 11759607
[No Abstract] [Full Text] [Related]
6. [Selective COX 2 inhibitor rofecoxib. To "defy" the pain].
MMW Fortschr Med; 2003 Aug; 145(31-32):56-7. PubMed ID: 14524083
[No Abstract] [Full Text] [Related]
7. Vioxx doctors wooed by Merck are now its foes.
Tesoriero HW
Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
[No Abstract] [Full Text] [Related]
8. New use approved for Vioxx.
FDA Consum; 2002; 36(4):3. PubMed ID: 12184302
[No Abstract] [Full Text] [Related]
9. [Overestimated].
Höer A; Häussler B
Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
[No Abstract] [Full Text] [Related]
10. [Really only Vioxx?].
Heinzl S
Med Monatsschr Pharm; 2004 Nov; 27(11):361. PubMed ID: 15566229
[No Abstract] [Full Text] [Related]
11. The lessons of Vioxx--drug safety and sales.
Waxman HA
N Engl J Med; 2005 Jun; 352(25):2576-8. PubMed ID: 15972862
[No Abstract] [Full Text] [Related]
12. [General practice study of therapy of acute pain. Patients prefer cox-2 inhibitors].
MMW Fortschr Med; 2004 May; 146(21):61. PubMed ID: 15373091
[No Abstract] [Full Text] [Related]
13. [Specific cyclo-oxygenase inhibitors. 2. Gastric toxicity?].
Blondon H
Presse Med; 2000 Mar; 29(9):482-3. PubMed ID: 10745938
[No Abstract] [Full Text] [Related]
14. Why don't we initiate more large simple randomized controlled trials?
Wright JM
CMAJ; 2003 Nov; 169(11):1170-1. PubMed ID: 14638653
[No Abstract] [Full Text] [Related]
15. [Meta-analysis on acute pain. Rofecoxib helped three quarters of patients].
MMW Fortschr Med; 2003 Aug; 145(31-32):57. PubMed ID: 14524084
[No Abstract] [Full Text] [Related]
16. [Selective COX-2 inhibitors--strong medicine for pain].
MMW Fortschr Med; 2004 Apr; 146(17):56-7. PubMed ID: 15224910
[No Abstract] [Full Text] [Related]
17. [Effective not only in rheumatism and arthrosis. Rofecoxib fights also acute pain].
MMW Fortschr Med; 2002 Feb; 144(7):68. PubMed ID: 11887740
[No Abstract] [Full Text] [Related]
18. [Prof. Bernd Simon on nonsteroidal anti-inflammatory drugs. Gastrointestinal complications are unpredictable].
Simon B
MMW Fortschr Med; 2001 May; 143(18):51-2. PubMed ID: 11387712
[No Abstract] [Full Text] [Related]
19. [Slime fight in the lay media. Were the Vioxx fatal cases kept secret?].
Zierenberg O
MMW Fortschr Med; 2004 Oct; 146(43):60. PubMed ID: 15559526
[No Abstract] [Full Text] [Related]
20. [Wrong information concerning rofecoxib].
Rygnestad T; Slørdal L
Tidsskr Nor Laegeforen; 2002 Aug; 122(20):2035. PubMed ID: 12555455
[No Abstract] [Full Text] [Related]
[Next] [New Search]
